Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 105.86
BTX's Cash to Debt is ranked higher than
74% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. BTX: 105.86 )
BTX' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 105.86

Equity to Asset 0.38
BTX's Equity to Asset is ranked higher than
57% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BTX: 0.38 )
BTX' s 10-Year Equity to Asset Range
Min: -45.87   Max: 0.99
Current: 0.38

-45.87
0.99
F-Score: 3
Z-Score: -0.67
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -976.18
BTX's Operating margin (%) is ranked higher than
58% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. BTX: -976.18 )
BTX' s 10-Year Operating margin (%) Range
Min: -9788.46   Max: -116.83
Current: -976.18

-9788.46
-116.83
Net-margin (%) -708.44
BTX's Net-margin (%) is ranked higher than
59% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. BTX: -708.44 )
BTX' s 10-Year Net-margin (%) Range
Min: -9471.15   Max: -137.48
Current: -708.44

-9471.15
-137.48
ROE (%) -173.85
BTX's ROE (%) is ranked higher than
51% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. BTX: -173.85 )
BTX' s 10-Year ROE (%) Range
Min: -2802.7   Max: -49.44
Current: -173.85

-2802.7
-49.44
ROA (%) -59.44
BTX's ROA (%) is ranked higher than
58% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. BTX: -59.44 )
BTX' s 10-Year ROA (%) Range
Min: -624.96   Max: -33.33
Current: -59.44

-624.96
-33.33
ROC (Joel Greenblatt) (%) -1840.95
BTX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. BTX: -1840.95 )
BTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21242.11   Max: -1501.85
Current: -1840.95

-21242.11
-1501.85
Revenue Growth (3Y)(%) -3.90
BTX's Revenue Growth (3Y)(%) is ranked higher than
74% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BTX: -3.90 )
BTX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -3.9

0
58.7
EBITDA Growth (3Y)(%) 22.30
BTX's EBITDA Growth (3Y)(%) is ranked higher than
89% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. BTX: 22.30 )
BTX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -48.9   Max: 63.9
Current: 22.3

-48.9
63.9
EPS Growth (3Y)(%) 16.30
BTX's EPS Growth (3Y)(%) is ranked higher than
87% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. BTX: 16.30 )
BTX' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.6   Max: 67.1
Current: 16.3

-35.6
67.1
» BTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

BTX Guru Trades in

BTX Guru Trades in

Q1 2014

BTX Guru Trades in Q1 2014

Jim Simons 51,700 sh (New)
» More
Q2 2014

BTX Guru Trades in Q2 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 16.00
BTX's P/B is ranked higher than
50% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. BTX: 16.00 )
BTX' s 10-Year P/B Range
Min: 5.65   Max: 83
Current: 16

5.65
83
P/S 57.90
BTX's P/S is ranked higher than
58% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. BTX: 57.90 )
BTX' s 10-Year P/S Range
Min: 4.83   Max: 124
Current: 57.9

4.83
124
EV-to-EBIT -7.43
BTX's EV-to-EBIT is ranked higher than
67% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: -7.43 )
BTX' s 10-Year EV-to-EBIT Range
Min: -71.6   Max: -1.1
Current: -7.43

-71.6
-1.1
Current Ratio 3.48
BTX's Current Ratio is ranked higher than
69% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. BTX: 3.48 )
BTX' s 10-Year Current Ratio Range
Min: 0.02   Max: 76
Current: 3.48

0.02
76
Quick Ratio 3.44
BTX's Quick Ratio is ranked higher than
70% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BTX: 3.44 )
BTX' s 10-Year Quick Ratio Range
Min: 0.02   Max: 74
Current: 3.44

0.02
74
Days Inventory 98.99
BTX's Days Inventory is ranked higher than
90% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BTX: 98.99 )
BTX' s 10-Year Days Inventory Range
Min: 44.57   Max: 97.03
Current: 98.99

44.57
97.03
Days Sales Outstanding 76.69
BTX's Days Sales Outstanding is ranked higher than
80% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. BTX: 76.69 )
BTX' s 10-Year Days Sales Outstanding Range
Min: 91.79   Max: 98.86
Current: 76.69

91.79
98.86

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.54
BTX's Price/Median PS Value is ranked higher than
76% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. BTX: 1.54 )
BTX' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 15.04
Current: 1.54

0.13
15.04
Earnings Yield (Greenblatt) -13.50
BTX's Earnings Yield (Greenblatt) is ranked higher than
56% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. BTX: -13.50 )
BTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -18.7   Max: 0
Current: -13.5

-18.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BT3.Germany,
BioTime Inc was incorporated in 1990 in the state of California. It is a biotechnology company engaged in two areas of biomedical research and product development. Its main focus is in the field of regenerative medicine; specifically human embryonic stem (hES) cell and induced pluripotent stem (iPS) cell technology. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. Its core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these pluripotent stem cells are being developed by the Company and its subsidiaries, for use in various fields of medicine, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. HyStem, Hextend, ESpy, PureStem, and PentaLyte are registered trademarks of the Company and Renevia, Premvia, ReGlyde, and ESpan are trademarks of the Company.
» More Articles for BTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: BTX, CWST, BKSC, STAG Jun 27 2011 
Weekly CEO Buys Highlight: PCYC, HLX, FSC, CREG, BTX Jun 25 2011 

More From Other Websites
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
BioTime to Present at the Jefferies 2015 Global Healthcare Conference May 20 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of... May 19 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure May 19 2015
BIOTIME INC Financials May 16 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
OncoCyte Corporation Completes Equity Financing Round May 14 2015
BIOTIME INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 14 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.6 Million Grant From Israel’s... May 13 2015
BIOTIME INC Files SEC form 8-K, Other Events May 13 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BioTime, Inc. Reports First Quarter 2015 Results and Recent Corporate Accomplishments May 11 2015
BIOTIME INC Files SEC form 8-K, Results of Operations and Financial Condition May 11 2015
BIOTIME INC Files SEC form 10-Q, Quarterly Report May 08 2015
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision May 04 2015
Cell Cure Neurosciences Announces Preclinical Efficacy Data Demonstrating OpRegen® Preserves Vision May 04 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure May 04 2015
BIOTIME INC Files SEC form 8-K, Regulation FD Disclosure Apr 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK